Skip to main content

Medigene Value Stock - Dividend - Research Selection

Medigene

ISIN: DE000A1X3W00, WKN: A1X3W0

Market price date: 08.01.2021
Market price: 4,95 EUR




Medigene Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 11-04-2020
Cash flow
Net operating cash flow -16.423.000
Capital Expenditures -1.428.000
Free cash flow -17.851.000
Balance sheet
Total Equity 81.823.000
Liabilities & Shareholders equity 109.215.000
Income statement
Net income -19.962.000
Eps (diluted) -0,810
Diluted shares outstanding 24.644.400
Net sales/revenue 10.511.000

Fundamental ratios calculated on: 08-01-2021

Ratios
Key figures 08-01-2021
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI-18,28
ROE74,92
Income statement
P/E-6,11
Div. Yield0,00%
P/B0,00
P/S11,61


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolMDG1.DE
Market Capitalization147.956.064,00 USD
CountryGermany
IndicesCDAX,Prime All Share
SectorsHealth service
Raw Data SourceIFRS in Millionen EUR
Stock Split2013-09-03,1.0000/4.0000; 2004-10-27,2105.000000/2104.000000; 2004-03-08,1214.000000/1211.000000
Internetwww.medigene.de


Description of the company

Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; EndoTAG-1 for the treatment of solid tumors; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and a research collaboration with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Martinsried, Germany.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.medigene.de